Jason Butler
Stock Analyst at JMP Securities
(3.02)
# 1,404
Out of 4,711 analysts
132
Total ratings
38.1%
Success rate
1.63%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jason Butler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABVX ABIVAX Société Anonyme | Initiates: Market Outperform | $33 | $7.65 | +331.37% | 1 | Dec 4, 2024 | |
| VIGL Vigil Neuroscience | Reiterates: Market Outperform | $22 | $1.70 | +1,194.12% | 4 | Nov 26, 2024 | |
| SYRS Syros Pharmaceuticals | Downgrades: Market Perform | n/a | $0.20 | - | 4 | Nov 13, 2024 | |
| HALO Halozyme Therapeutics | Maintains: Market Outperform | $72 → $73 | $46.96 | +55.45% | 13 | Nov 1, 2024 | |
| ARGX argenx SE | Maintains: Market Outperform | $497 → $606 | $623.82 | -2.86% | 6 | Nov 1, 2024 | |
| MRNS Marinus Pharmaceuticals | Downgrades: Market Perform | n/a | $0.23 | - | 3 | Oct 24, 2024 | |
| AQST Aquestive Therapeutics | Reiterates: Market Outperform | $9 | $3.65 | +146.58% | 7 | Oct 8, 2024 | |
| ZVRA Zevra Therapeutics | Initiates: Market Outperform | $17 | $8.49 | +100.24% | 1 | Sep 24, 2024 | |
| RZLT Rezolute | Reiterates: Market Outperform | $7 | $4.39 | +59.45% | 7 | Sep 20, 2024 | |
| GHRS GH Research | Reiterates: Market Outperform | $39 | $6.85 | +469.34% | 4 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $78 | $48.87 | +59.61% | 12 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.58 | - | 7 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $14 → $7 | $0.76 | +817.91% | 7 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $50 → $23 | $2.02 | +1,038.61% | 3 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $85 → $83 | $15.22 | +445.34% | 7 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $19 | $8.57 | +121.70% | 6 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $44 → $39 | $16.87 | +131.18% | 13 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $42 → $38 | $19.03 | +99.68% | 7 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $22 | $4.45 | +394.38% | 1 | Sep 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.16 | - | 1 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $1,200 | $0.57 | +210,796.31% | 1 | Dec 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $111 → $116 | $6.28 | +1,747.13% | 4 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $9 | $3.21 | +180.37% | 1 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $191 → $111 | $2.19 | +4,968.49% | 6 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.00 | - | 1 | Dec 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $24 → $21 | $83.45 | -74.84% | 5 | Aug 8, 2019 |
ABIVAX Société Anonyme
Dec 4, 2024
Initiates: Market Outperform
Price Target: $33
Current: $7.65
Upside: +331.37%
Vigil Neuroscience
Nov 26, 2024
Reiterates: Market Outperform
Price Target: $22
Current: $1.70
Upside: +1,194.12%
Syros Pharmaceuticals
Nov 13, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $0.20
Upside: -
Halozyme Therapeutics
Nov 1, 2024
Maintains: Market Outperform
Price Target: $72 → $73
Current: $46.96
Upside: +55.45%
argenx SE
Nov 1, 2024
Maintains: Market Outperform
Price Target: $497 → $606
Current: $623.82
Upside: -2.86%
Marinus Pharmaceuticals
Oct 24, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $0.23
Upside: -
Aquestive Therapeutics
Oct 8, 2024
Reiterates: Market Outperform
Price Target: $9
Current: $3.65
Upside: +146.58%
Zevra Therapeutics
Sep 24, 2024
Initiates: Market Outperform
Price Target: $17
Current: $8.49
Upside: +100.24%
Rezolute
Sep 20, 2024
Reiterates: Market Outperform
Price Target: $7
Current: $4.39
Upside: +59.45%
GH Research
Sep 4, 2024
Reiterates: Market Outperform
Price Target: $39
Current: $6.85
Upside: +469.34%
Sep 4, 2024
Reiterates: Market Outperform
Price Target: $78
Current: $48.87
Upside: +59.61%
Sep 4, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $0.58
Upside: -
Aug 15, 2024
Maintains: Market Outperform
Price Target: $14 → $7
Current: $0.76
Upside: +817.91%
Jul 26, 2024
Maintains: Market Outperform
Price Target: $50 → $23
Current: $2.02
Upside: +1,038.61%
May 9, 2024
Maintains: Market Outperform
Price Target: $85 → $83
Current: $15.22
Upside: +445.34%
Apr 9, 2024
Reiterates: Market Outperform
Price Target: $19
Current: $8.57
Upside: +121.70%
Mar 12, 2024
Maintains: Outperform
Price Target: $44 → $39
Current: $16.87
Upside: +131.18%
Nov 14, 2023
Maintains: Market Outperform
Price Target: $42 → $38
Current: $19.03
Upside: +99.68%
Sep 28, 2023
Initiates: Market Outperform
Price Target: $22
Current: $4.45
Upside: +394.38%
Oct 17, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $2.16
Upside: -
Dec 15, 2021
Initiates: Market Outperform
Price Target: $1,200
Current: $0.57
Upside: +210,796.31%
Nov 23, 2021
Maintains: Market Outperform
Price Target: $111 → $116
Current: $6.28
Upside: +1,747.13%
Nov 8, 2021
Maintains: Market Outperform
Price Target: $7 → $9
Current: $3.21
Upside: +180.37%
May 5, 2021
Maintains: Market Outperform
Price Target: $191 → $111
Current: $2.19
Upside: +4,968.49%
Dec 2, 2020
Downgrades: Market Perform
Price Target: n/a
Current: $1.00
Upside: -
Aug 8, 2019
Reiterates: Market Outperform
Price Target: $24 → $21
Current: $83.45
Upside: -74.84%